Quadrant Capital Group LLC Reduces Stake in DaVita Inc. (NYSE:DVA) (2024)

Quadrant Capital Group LLC decreased its stake in shares of DaVita Inc. (NYSE:DVA – Free Report) by 29.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 492 shares of the company’s stock after selling 202 shares during the period. Quadrant Capital Group LLC’s holdings in DaVita were worth $52,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in DaVita by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 6,175,029 shares of the company’s stock worth $583,725,000 after purchasing an additional 65,526 shares in the last quarter. Invesco Ltd. increased its stake in DaVita by 21.3% in the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock worth $157,606,000 after acquiring an additional 292,767 shares during the last quarter. Deutsche Bank AG increased its stake in DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after acquiring an additional 885,195 shares during the last quarter. Lazard Asset Management LLC increased its stake in DaVita by 8.7% in the 3rd quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock worth $79,916,000 after acquiring an additional 67,970 shares during the last quarter. Finally, Northern Trust Corp increased its stake in DaVita by 15.7% in the 3rd quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock worth $78,895,000 after acquiring an additional 113,508 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the sale, the director now owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.00% of the stock is owned by corporate insiders.

DaVita Price Performance

DVA opened at $138.54 on Tuesday. The stock’s 50 day simple moving average is $135.29 and its 200 day simple moving average is $119.62. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $145.04. The firm has a market cap of $12.15 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 1.06 and a beta of 1.04.

DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. During the same period last year, the company earned $1.58 EPS. DaVita’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, analysts predict that DaVita Inc. will post 9.62 earnings per share for the current year.

Analysts Set New Price Targets

DVA has been the topic of a number of research analyst reports. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 6th. Barclays increased their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. Truist Financial increased their price objective on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. Finally, UBS Group increased their price objective on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $144.67.

Check Out Our Latest Report on DaVita

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Articles

• Five stocks we like better than DaVita
• Compound Interest and Why It Matters When Investing
• Norwegian Cruise Line Sets Sail on Record Bookings Raised EPS
• Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
• The Best EV Stock You Haven’t Considered
• What is the FTSE 100 index?
• MarketBeat Week in Review – 5/20 – 5/24

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.